OR WAIT null SECS
February 12, 2025
Article
Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.
February 11, 2025
Iron administration was linked to a decrease in platelet counts, even in the absence of preexisting thrombocytosis.
February 07, 2025
More than 90% of patients with hemophilia B eliminated factor IX prophylaxis 4 years after treatment with etranacogene dezaparvovec (HEMGENIX) gene therapy.
Interim analysis of the Phase 3 FRONTIER3 trial found Mim8 well-tolerated in children with hemophilia A with and without inhibitors.
January 31, 2025
This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.
January 27, 2025
Peter Kranke, MD, MBA, MME, and colleagues call for clarifications to the August 2024 recommendations with more real-world considerations.
January 16, 2025
Axatilimab in 9 mg and 22 mg vial sizes are expected to launch in early February for the treatment of chronic graft-versus-host disease.
January 15, 2025
2 phase 3 trials show iptacopan improves fatigue, quality of life, and hematologic markers in C5i-experienced or -naive patients with paroxysmal nocturnal hemoglobinuria.
January 14, 2025
An infusion of ferric carboxymaltose in the third trimester significantly reduced anemia in pregnant women, surpassing the efficacy of iron tablets.
January 13, 2025
A new study highlights notable obesity-associated disruptions of iron metabolism, with higher hemoglobin and serum ferritin levels in pre-obese and obese cohorts.